VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
|
|
- ああす さわい
- 4 years ago
- Views:
Transcription
1 VENTANA ALK D5F3 Rabbit Monoclonal Antibody OptiView ALK D5F3
2 2 OptiView ALK D5F %31% 18% 80 85NSCLC 40% 1, ALK ALK 2 ALK 3 5% ALK EML4 EML4-ALK Coild-Coil ALK ALK 3,4,5 2 6 EGFR 50% KRAS 15% ALK 5% HER2 3% 100% MET 4% unknown 22% ALK 7 ALK ALK 8 ALK ALK ALK ALK ALK ALK
3 OptiView ALK D5F3 3 ALK OptiView ALK D5F3 ALK 9-12 OptiView ALK D5F3 FISHALK 3 OptiView ALK D5F3 ALK + + = OptiView AMP D5F3 ALK D5F3 OptiView DAB OptiView ULTRA XT XT GX ALK OptiView ALK D5F34 FISH 4 OptiView ALK D5F3 OptiView ALK D5F3 ALKDAB NordiQC OptiView ALK D5F3 13
4 4 OptiView ALK D5F3 OptiView ALK D5F3 ALK ALK NMP ALK 2007 EML4-ALK ALK ALK ALK 14 OptiView ALK D5F3 ALK D5F3 - DAB H2O2 HN OH DAB HN H2O2 OH OH H2O2 OH OptiView DAB - ALK D5F3 - OptiView DAB - OptiView ALK D5F3 ALK D5F OptiView ALK D5F3 OptiView ALK D5F3 15 ALK ALK FISH 16 ALK OptiView ALK D5F3 OptiView OptiView OptiView ALK D5F3 5A4
5 OptiView ALK D5F3 5 ALK OptiView ALK D5F3 OptiView ALK D5F EZX ALK D5F3 RxDx OptiView DAB OptiView 50 XT, GX OptiView DAB Cell Conditioning Pre-Primary Peroxidase Inhibitor Antibody OptiView Univ Linker OptiView Multimer OptiView Amplification OV AMP H2O2, OV Amplifier OV AMP Multimer Counterstain Post Counterstain CC1 92min Selected 16 min 12 min 12 min Selected 8 min 8 min Hematoxylin, 4 min Bluing, 4 min ULTRA ULTRA ALK U VENTANA ALK D5F3 Antibody Primary Counterstain Post Counterstain VENTANA ALK AB 16 min EU/Other Negative Control Hematoxylin, 4 min Bluing, 4 min OptiView ALK D5F3 NordiQCALK IHC ALK DAB DAB ALK ALK
6 6 OptiView ALK D5F3 OptiView ALK D5F ALK ALK ALK CD56 x20 x20
7 OptiView ALK D5F3 7 References 1., ganjoho.jp, , zangankyo.ncc.go.jp, Soda M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature Aug 2; Shaw AT, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol Sep 10; Pao W, et al. New driver mutations in non-small-cell lung cancer. Lancet Oncol Feb;12 2 : Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol Feb; ALK 2, 9. XALKORI Crizotinib Package Insert Thorne-Nuzzo T, et al. A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib. J Thorac Oncol Jan 29. pii S ZYKADIA ceritinib Package Insert Jean-Charles Soria, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer ASCEND-4 a randomised, open-label, phase 3 study. Lancet March Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010; Murry W. et al. An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators. Journal of Thoracic Oncology May; Greta Ali, et al. ALK Rearrangement in a Large Series of Consecutive Non Small Cell Lung Cancers. Arch Pathol Lab Med Nov;
8 東京都港区港南 カスタマーソリューションセンター VENTANA は ロシュ社の登録商標です 1078.TD.TMS.2000.PAB01-024A
VENTANA PD-L1 SP142 Rabbit Monoclonal Antibody OptiView PD-L1 SP142
VENTANA PD-L1 SP142 Rabbit Monoclonal Antibody OptiView PD-L1 SP142 2 OptiView PD-L1 SP142 OptiView PD-L1 SP142 OptiView PD-L1 SP142 PD-L1 OptiView PD-L1 SP142 PD-L1 OptiView PD-L1 SP142 PD-L1 OptiView
More informationLung Cancer diagnostic solutions
Lung Cancer diagnostic solutions 1 Lung Cancer diagnostic solutions 1 ALK D5F3 518-111175 790-4843 c-met SP44 518-108830 760-4430 SP65 518-109615 790-4467 CD56 MRQ-42 518-110710 760-4596 CEA TF3H8-1 2
More information橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
More informationスライド 1
QOL 1 Goldberg, JCO 22:23-30, 2004 N9741: Oxaliplatin in First Line (US) IR 200 mg/m 2 OX 85 mg/m 2 every 3 weeks Efficacy IFL FOLFOX4 > IFL IROX FOLFOX4 IROX OS TTP RR 15.0 mo 6.9 mo 31 % P=0.0001 P=0.0014
More information肺癌第50巻第4号
1 Department of Cancer and Thoracic Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Japan; 2 Department of Thoracic Surgery, Aichi Cancer Center, Japan;
More information437“ƒ
et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer
More information1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
More information欧州に見るマイナス金利が銀行に及ぼす影響
TEL 3-6733-17 E-mail 1 / 14 216 5 27 TEL 3-6733-17 E-mail 2 / 14 EU 2161 2146 2152 2127 2149 21412 2163 216 3.1%.1%...5%.6% 1.25%.65% CD.75%.5% 1.45% 1.2% 1 (2164 ).82%.97%.62%.51%.259% 3.325% 2161 1 6,4
More informationROWCatPathology_J.book
www.dako.jp IHC Solution Visualization Systems Number of Steps 5 4 3 2 1 LSAB TM 2 EnVision TM G 2 Doublestain EnVision TM DuoFLEX Doublestain LSAB TM + EnVision TM G 2 EnVision TM + EnVision TM FLEX 1
More information第79回_プログラム.indd
Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial
More informationMicrosoft Word ab205921_自動染色プロトコール_YU_IS.docx
抗 PD-L1 抗体 [clone 28-8] 動免疫組織染 装置別プロトコール PD-L1 RabMAb [clone 28-8] (ab205921) BioGenex 社 i6000( オフライン抗原賦活化 ) Leica 社 BOND RX( オンライン抗原賦活化 ) Ventana 社 Ultra( オフライン抗原賦活化 ) Dako 社 Omnis BioGenex 社 i6000 プロトコール
More informationスライド 1
1 2006 msv 2 2011 3 CT 2011 10mSv 10 40mSv 4 2012 217mSv 5 (CT) 2012 50 60mSv 6 2012 510mSv BRCA25 310 10mSv3% BRCA60-280% 3 5m Sv 1m Sv 12% . http://www.rea.or.jp/ire/pdf/report4.pdf 1.10 20 SMR 1.00
More informationHER2検査ガイド_h1_h4.ai
1Hofmann M, et al. Assessment of a HER2 scoring system for gastric cancer:results from a validation study. Histopathology 2008;52:797-805. 2Lee AH, et al. The effect of delay in fixation on HER2 expression
More informationPowerPoint プレゼンテーション
2017/6/9 第 27 回がん臨床研究フォーラム 大阪国際がんセンター 呼吸器内科西野和美 2017/6/9 第 27 回がん臨床研究フォーラム CO I 開示 大阪国際がんセンター西野和美 講演料 中外製薬ベーリンガーインゲルハイムアストラゼネカイーライリリー 肺癌薬物治療の変遷 Target Therapy Immunotherapy 1 次治療 ゲフィチニブ (EGFR-TKI) ペムブロリズマブ
More informationNL16-1_0329
No.16-1 March. 2012 JAMTTC News Letter http://jamttc.umin.jp/ Japanese Association for Molecular Target Therapy of Cancer 135-85503-8-31 TEL: 03-3520-0111 ext.5413 FAX: 03-3570-0484 ...1 JAMTTC2012...2...3...4...5
More informationSingle slice helical CT CT 1 2005 1 4 1. CT Anti-Lung Cancer Association: ALCA 1-5) 1993 9 10 ALCA (Nawa 6) ) single slice helical CT 10mm CT 2. 1 (http://www.thoracic-ctscreening.org/jpn/index.html )
More informationcontents
3 3 4 5 6 7 7 8 8 9 9 10 10 10 11 11 12 13 13 14 14 14 14 14 14 contents 3 3 4 5 6 7 7 8 8 9 9 10 10 10 11 11 12 13 13 14 14 14 14 14 14 01 1 22 3 3 44 studies 1 2 Hiroshima Univ. ACTIVITIES campus
More information求人面接資料PPT
Hair Salon TV etc. 250" 250" 200" 200" 150" 150" 100" 100" 50" 50" 0" 0" Nov)13" Dec)13" Jan)14" Feb)14" Mar)14" Apr)14" May)14" Jun)14" Jul)14" Dec)12" Jan)13" Feb)13" Mar)13" Apr)13"
More information20mg #tr#5*xlj lffin&+'.':, t) r+'z)vt '+D#J Centers for Medicare & Medicaid Sewices Garden AS et al. Preliminary results ofradiation Therapy Oncology Group 97-03: a randomized phase II trial of
More information食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
More informationRinku General Medical Center
Rinku General Medical Center 4860 100 1620 Ann Intern Med. 1966; 64: 328 40 CHOP 63 1 83 J Clin Oncol. 1998; 16: 20065-69 Febrile Neutropenia IDSA(Infectious Diseases Society of America) 2002 Guidelines
More information32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ
29 1 31 40 2014 31 Bisphosphonate related osteonecrosis of jaw; BRONJ 2008 4 2012 3 36 98 8 11 19 BRONJ 0 13 2 5 3 1 1 0 BP 4 15 10 5 α-streptococcus 0 BRONJ BRONJ BP I Paget 1 409-3898 1110 2014 1 27
More information08-g-”O−}„j‹ê-4.02
200( 96 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 Apr. 585 1 17 MIC 1. (Transtracheal aspiration: TTA) TTA TTA TTA 1400 TTA (diffuse panbronchiolitis, DPB) 1) erythromycin(em) EM 12.5% 87.5% 2,3) EM EM
More information<4D F736F F F696E74202D2094AD955C BD82BF82C482F F6E E63655B93C782DD8EE68
Polysomy 17 in Breast Cancer 2009 年 10 月 15 日 たちてん web conference 前回提示した症例 58 歳閉経後女性 右 MMK(T4bN1M0 Stage IIIB) に対して H11.8 月 Bt+Mn+Ax 試行 His ; IDC, t= 58mm, n= 9/22, HG3, ER/PR/HER2 = -/+/0 Adj ; ECx6 TAM
More information1) Garner J. S.: The Hospital Infection Control Practices Advisory Committee, CDC, Guidelines for Isolation Precautions in Hospitals, 1996. http://wonder.cdc.gov/wonder/prevguid/ p0000419/p0000419.asp.
More informationuntitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m
More information*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combinati
*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combination with angiotensin II induced hyperten sion chemotherapy
More information14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=
DeCEMBER, 17 No.34 HIV 169-73 1-1-1-13TEL 3-5937-4413:3 19:3 FAX 3-5937-443E-mail info@janpplus.jp http://janpplus.jp/!9-9-9!... 1-3 POSITIVE HIV/AIDS UNAIDS!... 4-5 JaNP+HIV Cafe Bar an opportunity...
More information7) G. N., A. A. Sondore et al.: The Use of Hyperbaric Oxygenation in Intensive Therapy of Patients with Liver Damage. VI Int. Cong. HBO Medicine, Moscow, Sept 2 `6:341, 1981 8) J. J. Moder, M. D.: Phagocytic
More informationuntitled
twatanab@oncoloplan.com http://www.oncoloplan.com I II - III IV Fig 3. Survival curves overall and according to response Bruzzi, P. et al. J Clin Oncol; 23:5117-5125 25 Copyright merican Society of Clinical
More informationuntitled
1) American College of Surgeons:Advanced Trauma Life Support Course Manual. American College of Surgeons 1997;103-112 24 2) American Society of Anesthesiologists Task Force:Practice guideline for blood
More informationThe Heart Healthy Tocotrienol Complex Tocomin SupraBio
The Heart Healthy Tocotrienol Complex Tocomin SupraBio The Heart Healthy Tocotrienol Complex Tocomin SupraBio 1. Fact Sheet No. 317; World Health Organization (WHO), 2007 2. LLOYD-JONES D. et al. Circulation
More information肺癌第49巻第1号
1 Department of Diagnostic Pathology, Graduate School of edicine, Chiba University, Japan; 2 Department of Thoracic Surgery, Chiba Rosai Hospital, Japan; 3 Work Environment Research Group, National Institute
More informationCHEMOTHERAPY AUG. 1982 VOL. 30 NO. 8 CHEMOTHERAPY Fig.1 Relation between various-closis of cefazolin and detection rate of organisms in heart blood of dying mice with E. coli and P. aeruginosa infection
More information小児感染免疫第23巻第1号
Vol. 23No. 163 42 HPV HPV 1113 HPV 42 HPV HPV HPV 1 1 510 1020 HPV 1020 510 HIV 0.1 0.005 HIV 2030 HIV 0.2 510 HPV 1020 15 HIV 2030 HIV HIV 0.2 0.1 Takeyuki Sato 2608677 181 64 2011 2 1 1518 6,000 513
More information初めに:
2 Copyrightc2008 JETRO. All rights reserved. FAX 03-5572-7044 ...5...6 (1)...7... 11... 11...12...14...15...15...16...17...18 (4)...21 (5)...21 (6)...23 4 Copyrightc2008 JETRO. All rights reserved. 5 Copyrightc2008
More information日本消化器外科学会雑誌第30巻第3号
Key words : gastric cancer, progltostic factor. multivariate analysis Factors selected after Coffelation- after Stepwise rnitrally check check H o s t l A g e C O 2 S e x C O 3 Pre-op. compliation O Treatment
More information肺癌患者におけるALK遺伝子検査の手引き
肺癌患者における ALK 融合遺伝子検査の手引き 第 1.0 版 2011 年 8 月 1 日バイオマーカー委員会コメント第 1.1 版 2011 年 10 月 12 日バイオマーカー委員会承認第 1.2 版 2011 年 11 月 2 日理事会で修正の上承認第 2.0 版 2015 年 6 月 6 日バイオマーカー委員会コメント第 2.1 版 2015 年 7 月 28 日バイオマーカー委員会承認第
More informationPowerPoint プレゼンテーション
* ** 117,320 70,293 109,140 49,830 93,402 45,744 60,986 31,875 47,318 28,829 45,367 18,186 29,025 12,838 27,822 11,970 20,734 10,823 19,994 10,336 * 2007 ** 2011 65% 25% 9 DNA P53, ATM G1 S G2 G1 M 1
More information1990 preimplantation genetic diagnosis: PGD ( )
Title Author(s) 日本における受精卵診断をめぐる論争 (1990 年代 ) - 争いの経過 - 利光, 恵子 Citation 医療 生命と倫理 社会. 7 P.67-P.85 Issue Date 2008-03-20 Text Version publisher URL https://doi.org/10.18910/12560 DOI 10.18910/12560 rights
More informationJHN Journal Club 手稲渓仁会病院
JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c
More information2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1
More information1) Asa, S. L., et al.: Immunohistochemical localization of neuron-specific enolase in the human hypophysis and pituitary adenoma, Arch. Pathol. Lab. Med., 108: 40 `43, 1984. 2) Chi, B. H. and Kim, R. C.:
More information; cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml Mφ 6 7, 8 9
32, 21-25, 2012 CASLE 1 1 80 26 6 5 4 cm 1 2 CEA 3 4 CEA 2 44 22 2 3 1.5 cm 22 1. 1 ; 6 5 4 cm 4. ; 2. ; 3. ; 5. 2 ; 120 ng/ml 0-40 5 Mφ 6 7, 8 9 23 6. ; 9. ; 7. ; 10. ; 8. 7 10 CK3 CK3 24 1,2 3 2 8% 4,5
More information*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells
*Criteria 1) B-marker positive 2) Variability in nuclear size and shape 3) Giant cells and multinucleated cells Abbreviation: LC=large cleaved nuclei, LNC=large non-cleaved nuclei, IMBL=immunoblastic nuclei,
More information請求記号:DVD 70- -1 栄光のフィレンツェ・ルネサンス 1 夜明け 55分
DVD 291- -482 64 DVD 520- -434 170 DVD 520- -435 173 DVD 520- -436 178 DVD 520- -437 94 DVD 520- -438 183 DVD 602.164- -508 38 DVD 70- -1 55 DVD 70- -2 55 DVD 70- -3 55 DVD 70- -4 55 DVD 70- -5 55 DVD
More information「適正なHER2検査のために」
乳癌における HER2 病理組織標本作製および 病理診断のガイドライン ( 案 ) 1. はじめに p. 2 2. 標本の準備 p. 2 3. Immunohistochemistry (IHC) 法 p. 2 4. In situ hybridization (ISH) 法 (FISH 法 DISH 法 ) p. 4 5. 病理診断と HER2 分子標的治療適応のフローチャート p. 6 6. 参考文献
More information1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
More information本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
More informationuntitled
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Int J Radiat Oncol Biol Phys 49 Cancer 101 Int J Radiat Oncol Biol Phys 60 Chest 124 Int J Radiat Oncol Biol Phys 56 Int J Radiat Oncol Biol Phys 49 Chest 124 Int J
More informationSpecial IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
More informationSTUDIES ON THE RELATION BETWEEN LATE DUMPING SYNDROME AND GLUCAGON RESPONCES TO GLUCOSE Taisuke MATSUI The First Department of Surgery, Nara Medical U
STUDIES ON THE RELATION BETWEEN LATE DUMPING SYNDROME AND GLUCAGON RESPONCES TO GLUCOSE Taisuke MATSUI The First Department of Surgery, Nara Medical University, Kashihara (Director: Prof. H. Nakano) This
More informationTable 1 Laboratory data on admission Fig. 1 Visual finding of the chest
A Case of Klinefelter Syndrome Associated with Mediastinal Germ Cell Tumor Presenting with a Prominent Gynecomastia Tomomi HARAI,*" Hiromichi TANEICHI,*1 Hisano SAKAKC Keiko NOMURA,*2 Hirokazu KANEGANE*2
More informationindd
Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf
More information_2009MAR.ren
ISSN 0389-5254 2009 No.2 MAR JAPAN AIRCRAFT PILOT ASSOCIATION C O N T E N T S No.313 2009 No.2 MAR é 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR 2009 MAR
More informationISSN 慈大 2017 feb 呼吸器疾患研究会誌 Jikei Journal of Chest Diseases 豊胸術後にシェーグレン症候群と胸膜肥厚を認めたヒトアジュバント病の 1 例花田豪郎ほか 1 第 90 回研究会記録 2 胸部 CT でスリガラス状陰影
ISSN 2189-9770 慈大 2017 feb. 29-1 呼吸器疾患研究会誌 Jikei Journal of Chest Diseases 豊胸術後にシェーグレン症候群と胸膜肥厚を認めたヒトアジュバント病の 1 例花田豪郎ほか 1 第 90 回研究会記録 2 胸部 CT でスリガラス状陰影を呈した左肺腫瘍の 1 切除例米山果織ほか 3 肺がんの新しい薬物療法 免疫チェックポイント阻害薬 滝口裕一
More informationc a a ca c c% c11 c12 % s & %
c a a ca c c% c11 c12 % s & % c13 c14 cc c15 %s & % c16 c211 c21% c212 c21% c213 c21% c214 c21% c215 c21% c216 c21% c23 & & % c24 c25 c311 c312 % c31 c315 c32 c33 c34 % c35 c36 c37 c411 c N N c413 c c414c
More informationUnderstanding Stem Cell Transplant 2007
Understanding Stem Cell Transplant IMF International Myeloma Foundation 12650 Riverside Drive, Suite 206 North Hollywood, CA 91607 USA Telephone: 800-452-CURE (2873) (USA & Canada) 818-487-7455 Fax: 818-487-7454
More information名称未設定-1
Study on Clinical Factors Affecting the Fungal Culture Test - Relevance of Dry Mouth - Yoshiko YAMAMURA, Yukihiro MOMOTA, Hideyuki TAKANO, Koichi KANI, Katsumi MOTEGI, Fumihiro MATSUMOTO, Masayuki AZUMA
More information胆石症
,. vs 64 .. vs. -, Ransohoff DF, Gracie W. Treatment of gallstones. Ann Intern Med ; 119 : - Halldestam I, Enell EL, Kullman E, et al. Development of symptoms and complications in individuals with asymptomatic
More information3) Beresford SAA, Weiss NS, Voigt LF, et al: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458-461, 1997 4) Daly
More information表1_表4
HN- 95 HN- 93 HN- 90 HN- 87 HN- 85 HN- 82 HN- 80 HN- 77 HN- 75 HN- 72 HN- 70 HN- 67 HN- 65 HN- 60 HN- 55 HN- 50 HN- 45 HN- 40 HN- 35 HN- 30 HN- 25 HN- 20 HN- 15 HN- 10 H02-80H H02-80L H02-70T H02-60H H05-60F
More information極地研 no174.indd
C O N T E N T S 02 10 13 no.174 June.2005 TOPICS06 1 45 46 3 12 4546 47 14 10 15 15 16 NEWS no.174 june.2005 0 100 200 300 400 500 600 700 100 100 Diameter,nm 10 10 45 20042 Feb Mar Apr May Jun Jul Aug
More informationPowerPoint プレゼンテーション
再発腫瘍の個別化医療 京都大学医学研究科標的治療腫瘍学講座 新倉直樹 乳癌の治療におけるバイオマーカー 原発腫瘍 Months/years 再発腫瘍 Months/years Progression ER PgR HER2 Ki67? ER PgR HER2 腫瘍の性格や治療選択が原発腫瘍もしくは再発腫瘍内で同じでいいのか? Abbreviations: ER, oestrogen receptor;
More informationE Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
More informationNo.19
Views and Actions C Points of View boxwhisker plot EU ICH http wwwinfopmdagojp n n n n n n No n n n n n n pi pii pi pii pi pii n n n PKPD No HTBD HTBD CD LHRH RS HTBD EGFR AT DMARD HTBD HTBD TNFα α HMGCoA
More informationSBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
More informationuntitled
260 250 200 150 10 100 50 0 1960 1965 1970 1975 1980 1985 1985 1995 2000 2005 25% 56% 66% 60% 90 80 70 60 50 40 30 20 10 0 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 4 1999 1990 2003 2005 2010 500,000 70,000 100,000
More informationMicrosoft Word - ALK遺伝子検査の手引き ver docx
肺癌患者における ALK 融合遺伝 検査の 引き 第 1.0 版 2011 年 8 1 バイオマーカー委員会コメント第 1.1 版 2011 年 10 12 バイオマーカー委員会承認第 1.2 版 2011 年 11 2 理事会で修正の上承認第 2.0 版 2015 年 6 6 バイオマーカー委員会コメント第 2.1 版 2015 年 7 28 バイオマーカー委員会承認第 2.1 版 2015 年
More information_02.indd
30, 11-16, 2010 Z Z score Computed tomography ROC analysis 3 CT 1,2 CT 1/3 3 5 CT CT 6 7,8 MCA ASPECTS Alberta Stroke Programme Early CT Score 4 10 CT ASPECTS 50% 9 Z 10 CT Z CT 10 Z Z Z receiver operating
More information62 No.11
Newsletter of the Tottori Prefectural Museum MARCH No. 11 62 No.11 No.11 73 4 No.11 No.11 5 62 No.11 No.11 73 INFORMATION LECTURE FIELD STUDY SATURDAY ART FEVER 4 ARL. 5 MAY. 6 JUN. 7 JUL. MUSEUM PRESS
More information090825_Sakate_for_dist.pptx
21 子 比 Evola 用 http://www.h-invitational.jp/evola/ 手龍一 2009 8 月 25 日 火 心 H-InvDBEvola 子 子 子 子 子 日 比 Evola 用 比 子 Evola 方 比 子 Evola 子 H-InvDB 6 子 比 子 生 子 生 生 片 方 比 長 大 子 生 長 生 22,496 子 13 生 長 魚 比 http://www.h-invitational.jp/g-compass/
More information50-3ガイド10ポ.indd
25 7 乳房専用 PET 診療ガイドライン作成メンバー PET 1 はじめに PET 18 F-2- -2- -D- FDG 14 12 FDG-PET FDG-PET 1) T1b 0.5 cm 1.0 cm T1c 1.0 cm 2.0 cm P=0.003 1.0 cm 2) MRI FDG-PET PET 1 cm FDG FDG 1 対向型乳房専用 PET 装置 2 2 3 6) 2 4
More information.K.C.h...C...ren
4 quality of life QOL QOL QOL 3 QOL 19 mmhg 16 mmhg 14 mmhg 1 2 7 20 30 QOL QOL QOL QOL QOL QOL QOL 4 1 1 1 2 1 2 3 1 2 4 2 2 1 2 2 2 2 1 2 3 QOL 3 2 1 1 5 1 1 2 1 Abraham Wise 1 Nd YAG 2 1 200 500 200
More informationA pp CALL College Life CD-ROM Development of CD-ROM English Teaching Materials, College Life Series, for Improving English Communica
A CALL College Life CD-ROM Development of CD-ROM English Teaching Materials, College Life Series, for Improving English Communicative Skills of Japanese College Students The purpose of the present study
More information膵癌超音波診(案)
1 2 3 4 5 6 7 8 9 10 2009 7 6 2 a. invasive ductal carcinoma * 1 b. endocrine neoplasm c. Solid pseudopapillary neoplasm d. tumor producing pancreatitis * 2 * 1 invasive ductal carcinomas papillary adenocarcinoma
More information本文
Apr 11, 213 (3-3497-3675) miwa-y @itochu.co.jp (3-3497-6284) maruyama-yo @itochu.co.jp 1. (1) (2) (3 (4) 2. (1)3 (2) (3)J (4) (5) (6) (7) (8) (9) (1) 46 3. Summary 2 2% 2 13 13 13 J 79 46 13 46 4 34 2%
More informationSICE東北支部研究集会資料(2017年)
307 (2017.2.27) 307-8 Deep Convolutional Neural Network X Detecting Masses in Mammograms Based on Transfer Learning of A Deep Convolutional Neural Network Shintaro Suzuki, Xiaoyong Zhang, Noriyasu Homma,
More informationuntitled
18 12 10 40 H5N1 2005 11 WHO 2005 12 2006 6 (H5N1) 10 25 1,700 ( 1,300 2,500 ) 200 53 64 17 30% 3,785,000 291,200 3 14,100 4 30% 57,600 4,430 3 1,150 320 210 4 2% 0.56% () ) 1 10 2 3A (2B) 3B 4A5A 6A 4B
More information400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
More information日本内科学会雑誌第105巻第9号
肺がんの分子標的治療 高橋和久 Key words 肺がん, 分子標的治療,EGFR,EML4-ALK, 抗 PD-1 抗体, 耐性, バイオマーカー はじめに進行非小細胞肺がんの治療成績は明らかに向上している.7 年に報告された4 種類の抗がん薬 2 剤併用療法を比較した第 III 相臨床試験 (FACS 研 ) での生存期間中央値は1 年前後であったが 1),PS(performance status)
More informationDynalTransplantDiagnostic.indd
2011 1 SeCore HLA SBT 1 2 AllSet + Gold SSP HLA 7 3 SSP UniTray HLA 11 4 27 5 32 ii 1 SeCore HLA SBT SeCore 2 SeCore HLA SBT SeCore 3 SeCore 4 HLA-I 5 HLA-II 5 utype 5 GSSP 6 1 SeCore HLA SBT Sequencing
More informationc c & % c 0 c N r l % *# 5 c c% c c % c c c % % c % % % c j % % % % % % % % &% &% % a % a &% c % cc % & s& cc c c & c & % c & c c & % % %c c %c & c % & % %c c %c & c % % % % % c c c a 28 % c% 13 5 6
More informationHEART'S Original A case of Brugada syndrome with a high defibrillation threshold in which defibrillation was successful by Active Can off defibrillation Keisuke Kawachi, Yukei Higashi, Yuuki Honda, Kouhei
More information8 20 symptom free 2 NEJM Clinical Practice fluticasone 1 2 fluticasone IgE 100U/ml 1819 Bostock 1 A Mycobacterium Toxoplasma
The Lancet, vol 378, Dec.17/24/31,2011 Alexander N Greiner USA Peter W Hellings, Guiseppina Rotiroti Glenis K Scadding The Lancet, Dec. 17/24/31, 2011 http://www.allergy.go.jp/allergy/guideline/04/index.html
More information特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
More informationuntitled
2303 16 2 9 1 14 5 31 (423) 1 (4), (6) C55H84ClN17O21S3 HCl (BLM-A2) 1487.47 11 2 1 4 104 2 14 5 31 [ ] ( ) ( ) 1. 15mg 30mg( ) 5 20mL 1 5mg( ) 2. 3 15mg 30mg( ) 5mL 1mg( ) 1mL 3. 5mg 15mg( ) 4. 1 2 1
More information終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
More information